Heart failure with mildly reduced ejection fraction, or HFmrEF, can feel confusing because it sits between reduced and preserved ejection fraction, but the treatment goal is straightforward: you want to reduce symptoms, prevent hospitalizations, and lower the risk of death by using evidence-based heart failure therapy and treating the causes that are driving the condition. Current guidelines define HFmrEF as left ventricular ejection fraction 41%–49%, with objective evidence of increased filling pressures supporting the diagnosis.
What HFmrEF means
HFmrEF is not just a number on an echocardiogram. You may still have significant heart failure symptoms even when the ejection fraction is only mildly reduced, and the condition often overlaps with the physiology seen in HFrEF and HFpEF. The 2022 AHA/ACC/HFSA guideline notes that HFmrEF patients often sit on a dynamic trajectory, sometimes improving from HFrEF or worsening toward HFrEF, so your treatment should address both current symptoms and future risk.
That matters because the most effective strategy is rarely a single drug. You usually need a combination of therapies, regular reassessment, and careful attention to blood pressure, kidney function, volume status, rhythm problems, and comorbid disease.
Core treatment goals
Your treatment should aim at four practical targets. First, you want to relieve congestion and breathlessness. Second, you want to prevent repeat decompensation and hospital admission. Third, you want to slow or reverse adverse remodeling of the heart. Fourth, you want to improve survival when evidence supports it.
In HFmrEF, the strongest treatment evidence has shifted toward using therapies that also benefit HFrEF, especially SGLT2 inhibitors, and toward selecting additional neurohormonal therapies in appropriate patients. A recent network meta-analysis found that ARNI, MRA, and SGLT2 inhibitors each reduced the composite outcome compared with placebo, with the largest benefit seen in combination therapy, while SGLT2 inhibitors showed consistent benefit across ejection fraction subgroups.
Medicines that help
SGLT2 inhibitors
SGLT2 inhibitors are now the clearest foundation drug class for HFmrEF. The ESC 2023 update recommends them for HFmrEF to improve prognosis, and the same update describes them as the only medication class that should be given to all heart failure patients for prognostic benefit independent of ejection fraction.
This class includes agents such as dapagliflozin and empagliflozin. In practice, you use them not because you have diabetes alone, but because they lower heart failure events and are generally well tolerated in suitable patients. The treatment decision still depends on renal function, blood pressure, volume status, and contraindications, but for many people with HFmrEF, an SGLT2 inhibitor should be an early choice rather than a late add-on.
Beta blockers
Beta blockers matter when you have a heart failure phenotype that resembles HFrEF, especially when tachycardia, ischemic heart disease, or prior reduced EF is part of the story. Evidence in HFmrEF is less uniform than in classic HFrEF, but the 2022 AHA/ACC/HFSA guidance and later analyses support using HFrEF-like therapy in selected HFmrEF patients, especially when the clinical picture suggests benefit.
You usually want evidence-based beta blockers rather than nonselective rate-slowing drugs chosen for convenience. The practical effect is better heart rate control, lower myocardial oxygen demand, improved filling time, and possible reduction in arrhythmic burden.
ACE inhibitors and ARBs
ACE inhibitors and ARBs are still relevant, especially when you need blood pressure control, afterload reduction, or treatment of ischemic or hypertensive heart disease. The evidence in HFmrEF is not as strong as in HFrEF, but they remain reasonable options in selected patients, particularly if you have a prior reduced EF, hypertension, diabetes, or post-MI remodeling.
You should think of these drugs as part of a broader remodeling strategy. They can help reduce neurohormonal activation and may be especially useful when another first-line agent is not tolerated or when you need layered therapy.
ARNI
Angiotensin receptor-neprilysin inhibitor therapy, especially sacubitril/valsartan, has emerged as one of the more important options for HFmrEF, particularly near the lower end of the EF range. The evidence synthesis in the 2024 network meta-analysis found that ARNI reduced the primary composite outcome versus placebo, and the combination of ARNI with MRA and SGLT2 inhibitor produced the largest overall benefit.
In practice, you consider ARNI when symptoms persist, when blood pressure allows it, and when you want a stronger disease-modifying option than a simple ACE inhibitor or ARB alone. You also need to check for prior ACE inhibitor use and the required washout period before switching.
Mineralocorticoid receptor antagonists
MRAs such as spironolactone and eplerenone also deserve attention in HFmrEF, especially when congestion, remodeling risk, or recurrent hospitalization is a concern. The network meta-analysis found that MRAs contributed to outcome reduction, and the ESC update supports their use as part of the “fantastic four” approach after decompensation.
The main limits are hyperkalemia and worsening renal function. That means you need monitoring after initiation and after dose changes, not just a prescription.
Diuretics for symptoms
Diuretics do not usually improve long-term survival by themselves, but they are essential when you have fluid overload. If you have leg swelling, abdominal bloating, orthopnea, elevated jugular venous pressure, or pulmonary congestion, loop diuretics can quickly improve symptoms and restore function. The AHA/ACC guideline emphasizes using clinical congestion to guide titration of therapy, including diuretics.
You should see diuretics as symptom control, not as the whole strategy. They treat the fluid problem, while the neurohormonal drugs treat the disease process.
Iron deficiency and anemia
Iron deficiency matters in HFmrEF because it can worsen fatigue, exercise tolerance, and quality of life. The ESC 2023 update gives a class IIa recommendation for intravenous ferric carboxymaltose or ferric derisomaltose in patients with HFrEF or HFmrEF and iron deficiency.
That means you should not ignore low ferritin or transferrin saturation just because the hemoglobin looks “almost normal.” If iron deficiency is present, treatment may improve how you feel and function, even before any dramatic change appears on an echocardiogram.
Blood pressure and rhythm control
HFmrEF often improves when you treat the conditions that continue to strain the heart. Hypertension is a major cause of heart failure, and controlling it reduces afterload and may help stabilize symptoms and remodeling. The AHA/ACC guideline also highlights the importance of finding the cause of HF because treatment may change depending on whether the driver is ischemia, hypertension, valvular disease, arrhythmia, or another cardiomyopathy.
Atrial fibrillation deserves special attention because it can worsen filling, reduce cardiac output, and raise symptoms even when the EF is only mildly reduced. If you have AF, you may need rate control, rhythm control, and anticoagulation based on stroke risk, along with HF therapy tailored to your hemodynamics.
Treat the cause
You get better results when you treat the reason the EF is mildly reduced, not just the EF number itself. Common causes include ischemic heart disease, hypertension, valvular disease, cardiomyopathy, myocarditis, tachycardia-mediated dysfunction, infiltrative disease, and toxic exposures such as alcohol or cardiotoxic drugs. The AHA/ACC guideline explicitly emphasizes determining the cause because specific therapies may be needed.
For example, if coronary artery disease is driving symptoms, revascularization may matter more than adding another blood pressure drug. If valvular disease is present, repair or replacement may change the course of the disease. If tachycardia is the main driver, controlling the rhythm may improve EF over time.
Lifestyle treatment
Medication alone is not enough. You also need salt awareness, fluid management when congestion is present, regular physical activity when stable, weight control, smoking cessation, and avoidance of alcohol or other cardiotoxic substances when relevant. These measures support symptom control and reduce the chance of worsening heart failure.
You should also pay close attention to vaccinations, sleep apnea, diabetes, obesity, and kidney disease because these conditions often worsen HFmrEF. The AHA/ACC guideline frames heart failure care as broader than drugs alone, with prevention and comorbidity management built into the treatment plan.
Monitoring and follow-up
HFmrEF treatment works best when you reassess regularly. You should monitor symptoms, blood pressure, heart rate, kidney function, electrolytes, weight, and congestion after starting or changing therapy. The AHA/ACC guideline notes that repeat imaging is useful when results will affect care, and EF trajectory matters because EF can improve or decline over time.
This is especially important if you started treatment after decompensation or if your EF sits near the lower end of the HFmrEF range. A repeat echocardiogram can show whether you are improving into a more stable category or moving toward HFrEF, which may change how aggressively you treat.
When disease is advanced
If you keep getting worse despite standard therapy, the problem may no longer be “routine HFmrEF.” Recurrent admissions, persistent congestion, low exercise tolerance, rising natriuretic peptides, worsening kidney function, or intolerance of foundational therapy should prompt a deeper review of the diagnosis, adherence, triggers, and possible specialist referral. The AHA/ACC guideline defines advanced HF as marked symptoms with recurrent hospitalizations despite attempts to optimize guideline-directed therapy.
At that point, you may need a heart failure specialist, advanced imaging, ischemic evaluation, device consideration in selected cases, or a more detailed search for less obvious causes such as amyloidosis or inflammatory cardiomyopathy. The point is to avoid treating a worsening phenotype as if it were stable mild disease.
Practical treatment approach
A simple way to think about HFmrEF treatment is to start with the therapies that lower risk and improve symptoms, then layer treatment based on your blood pressure, kidney function, congestion, rhythm, and cause of disease. For many patients, that means an SGLT2 inhibitor early, diuretics when congested, and then consideration of ARNI, beta blocker, ACE inhibitor or ARB, and MRA when appropriate. Evidence increasingly supports combination therapy rather than a one-drug approach.
For example, if you have HFmrEF with edema, hypertension, and prior MI, your treatment path may include a loop diuretic for congestion, an SGLT2 inhibitor, a beta blocker, and either an ARNI, ACE inhibitor, or ARB depending on blood pressure and tolerance. If you also have iron deficiency, you should correct it. If atrial fibrillation or ischemia is driving the syndrome, you should treat those problems directly.
What matters most
You should not treat HFmrEF as “almost normal” heart failure. The evidence shows that it carries real risk and responds to active treatment, especially with SGLT2 inhibitors and, in selected patients, layered neurohormonal therapy. The most useful plan combines symptom relief, disease-modifying medication, cause-specific treatment, and close follow-up.